Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?
Journal Information
Full Title: Ther Adv Med Oncol
Abbreviation: Ther Adv Med Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"RDM: The author declares that there are no conflicts of interest.: VLC: Consultant for Monteris Medical Inc.: SBG: Declares research funding from AstraZeneca, Boehringer Ingelheim, and Mirati. Consulting/advisory board member for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Amgen, Blueprint Medicine, Sanofi Genzyme, Daiichi–Sankyo, Regeneron, Takeda, Janssen, Summit Therapeutics, and Merck."
Funding Disclosure
Evidence found in paper:
"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025